Today: October 18, 2017, 1:37 pm

New Study: Primary Biliary Cirrhosis - Pipeline Review, H2 2017

Recently published research from Global Markets Direct, "Primary Biliary Cirrhosis - Pipeline Review, H2 2017", is now available at Fast Market Research
New Study: Primary Biliary Cirrhosis - Pipeline Review, H2 2017 2017-07-17 15:23:50
Primary Biliary Cirrhosis - Pipeline Review, H2 2017


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

Full Report Details at
- ..

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 1, 11, 5, 1 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

* The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
* The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
* The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
* The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
* The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
* The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
* The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
* The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

Reasons to Get this Report

* Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
* Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
* Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
* Classify potential new clients or partners in the target demographic.
* Develop tactical initiatives by understanding the focus areas of leading companies.
* Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
* Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

Press Information

Published by
Bill Thompson

# 785 Words
Related Articles
More From The Author
Electricity and Power (Construction) in Singapore: Market [..]
The electricity and power category covers construction activities related to power generation and transmission and include buildings [..]
Residential Construction Market in Australia: Market Size, [..]
Residential construction market covers new construction, renovation and demolition of residential buildings such as houses, townhouses, [..]
Now Available: Shotcrete Accelerator Market - Global [..]
Shotcrete Accelerator Market by Type (Alkali Free, Alkaline Aluminate, Alkaline Silicate), Grade (Liquid, Powdered), Process (Wet [..]
"Transportation Management System Market - Global Forecast [..]
Transportation Management System Market by Transportation Mode (Railways and Roadways), Component (Solution Type, Hardware, and [..]
BRIC Neurological Diagnostic Equipment Market Outlook to [..]
BRIC Neurological Diagnostic Equipment Market Outlook to 2023 Summary GlobalData's new report, "BRIC Neurological Diagnostic Equipment [..]
More From Health
“Reverse Abscopal Effect” in Rheumatoid Arthritis Using [..]
Biotech Holdings Announces Effective Induction of “Reverse Abscopal Effect” in Rheumatoid Arthritis Using Procell Activated Stem [..]
Air Optix Aqua Contacts from Alcon Keeps [..]
Alcon Laboratories’ Air Optix Aqua 6 pack contact lenses bring together two advanced technologies designed to provide long-lasting [..]
Simple Biomechanical Test could aid Implant Success
Tsukuba, Japan, Oct 10, 2017 - (ACN Newswire) - The quality of the tissue-implant interface is key to the success [..]
Daily Disposable Wear from Sauflon Clariti Keeps [..]
Sauflon Clariti is designed to give customers daily disposable lenses with the benefits of silicone hydrogel material and AquaGen [..]
Understanding Prescription Opioid Addiction, Riverside Clinic [..]
A recent report on ABC News says over the past decade the use of opioid-based prescription painkillers has quadrupled. Over [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.